Theranexus (EPA:ALTHX) | WebDisclosure

Basculer en Français

9784	Companies
196006	Keywords
127065	Articles
104238	Press releases

Home
Companies
Theranexus

PRESS RELEASE

published on 11/19/2024 at 18:00, 1 year 2 months ago

Theranexus fait le point sur son programme Batten-1 dans la maladie de Batten CLN3
Présentation des résultats prometteurs de l'essai de phase I/II de Batten-1 par Theranexus et BBDF lors du Child Neurology Society Annual Meeting. Signaux positifs sur l'acuité visuelle de patients atteints de CLN3

Essai Clinique Theranexus Maladie De Batten CLN3 BBDF Acuité Visuelle
PRESS RELEASE

published on 11/19/2024 at 18:00, 1 year 2 months ago

Update on the Theranexus' Batten-1 project in CLN3 Batten's disease
Theranexus and BBDF present positive results of Batten-1 trial in CLN3 Batten disease patients, showing safety and efficacy of miglustat. Expanded use indicates potential in visual acuity stabilization

Theranexus BBDF Batten-1 Trial CLN3 Batten Disease Miglustat
BRIEF

published on 10/23/2024 at 18:05, 1 year 3 months ago

Theranexus Annonce Sa Trésorerie au 30 Septembre 2024

Trésorerie Maladie De Batten Partenariats Industriels Miglustat Crédit Impôt Recherche
BRIEF

published on 10/23/2024 at 18:05, 1 year 3 months ago

Theranexus Announces Its Cash Position as of September 30, 2024

Treasury Batten Disease Miglustat Research Tax Credit Industrial Partnerships
PRESS RELEASE

published on 10/23/2024 at 18:00, 1 year 3 months ago

THERANEXUS PUBLIE SA POSITION DE TRÉSORERIE AU 30 SEPTEMBRE 2024
Theranexus annonce sa trésorerie au 30 septembre 2024 avec 1,9 M€ disponible, incluant le Crédit Impôt Recherche de 785 K€. Projet d'enregistrement en Europe et phase 3 dans la maladie de Batten

Trésorerie Phase 3 Theranexus Maladies Neurologiques CIR
PRESS RELEASE

published on 10/23/2024 at 18:00, 1 year 3 months ago

THERANEXUS ANNOUNCES ITS CASH POSITION AS OF SEPTEMBER 30, 2024
Theranexus reports €1.9 million cash position as of September 30, 2024, with plans for product registrations and phase 3 trials in rare neurological diseases

Cash Position Biopharmaceutical Theranexus Rare Neurological Diseases Product Registrations
BRIEF

published on 10/17/2024 at 18:05, 1 year 3 months ago

Theranexus s'associe à Synerlab pour une avancée dans le traitement de Niemann-Pick C

Theranexus EMA Synerlab Miglustat Niemann-Pick C
BRIEF

published on 10/17/2024 at 18:05, 1 year 3 months ago

Theranexus partners with Synerlab for a breakthrough in the treatment of Niemann-Pick C

Theranexus EMA Synerlab Miglustat Niemann-Pick C
PRESS RELEASE

published on 10/17/2024 at 18:00, 1 year 3 months ago

THERANEXUS S'ASSOCIE À SYNERLAB POUR PRÉPARER LA COMMERCIALISATION DE SA FORMULATION PÉDIATRIQUE DANS LA MALADIE DE NIEMANN-PICK DE TYPE C
Theranexus et Synerlab annoncent un partenariat pour la production du traitement Mig-OS pour la maladie de Niemann-Pick de type C. Lancement commercial prévu dès 2026

Theranexus EMA Synerlab Mig-OS Maladie De Niemann-Pick De Type C
PRESS RELEASE

published on 10/17/2024 at 18:00, 1 year 3 months ago

THERANEXUS JOINS UP WITH SYNERLAB TO PREPARE THE COMMERCIALIZATION OF ITS PEDIATRIC FORMULATION IN NIEMANN-PICK TYPE C DISEASE
Theranexus partners with Synerlab to produce oral solution of miglustat for Niemann-Pick type C disease, aiming for EMA approval and commercialization by 2026. Novel pediatric formulation Mig-OS provides new therapeutic option for NPC patients

Theranexus Synerlab Miglustat Niemann-Pick Type C Disease EMA Approval

Accesswire

Published on 02/02/2026 at 23:55, 2 hours 32 minutes ago

2026 Tunkillia Development Drilling Programs Begin
Published on 02/02/2026 at 23:55, 2 hours 32 minutes ago

55 North Mining Announces Winter Exploration Drill Program at Last Hope Gold Project
Published on 02/02/2026 at 23:25, 3 hours 2 minutes ago

Western Announces Sale of GlassMasters Investment
Published on 02/02/2026 at 22:05, 4 hours 22 minutes ago

Organto Foods to Attend Fruit Logistica 2026 in Berlin, Germany From February 4-6, 2026
Published on 02/02/2026 at 15:00, 11 hours 27 minutes ago

Jericho Energy Ventures Strategically Terminates SmartKem LOI to Advance Independent Data Center Energy Infrastructure Platform

View all ACCESSWIRE

EQS Group

Published on 02/02/2026 at 20:00, 6 hours 27 minutes ago

CGTN AMERICA & CCTV UN: Cultural Event Celebrating the Spring Festival and the 55th Anniversary of China-U.S. Ping-Pong Diplomacy
Published on 02/02/2026 at 19:57, 6 hours 29 minutes ago

US federal court grants preliminary injunction allowing Sunrise Wind construction to resume
Published on 02/02/2026 at 19:42, 6 hours 44 minutes ago

EQS-Adhoc: ProSiebenSat.1 publishes preliminary figures for financial year 2025
Published on 02/02/2026 at 19:05, 7 hours 22 minutes ago

Virtual Science AI launches the life science industry's first medical congress AI solution for real-time event conversational intelligence
Published on 02/02/2026 at 19:00, 7 hours 27 minutes ago

PATRIMOINE ET COMMERCE: INFORMATIONS RELATIVES AU NOMBRE TOTAL DE DROITS DE VOTE ET AU NOMBRE D’ACTIONS COMPOSANT LE CAPITAL SOCIAL AU TITRE DE L’ARTICLE 223-16 DU REGLEMENT GENERAL DE L'AMF

Les Echos

Published on 02/02/2026 at 18:23, 8 hours 3 minutes ago

Monthly disclosure of the total number of shares and voting rights - January 2026
Published on 02/02/2026 at 18:23, 8 hours 3 minutes ago

TF1 - Déclaration mensuelle des actions et droits de vote - Janvier 2026
Published on 02/02/2026 at 18:00, 8 hours 27 minutes ago

Covivio - Information on total number of voting rights and share capital
Published on 02/02/2026 at 18:00, 8 hours 27 minutes ago

Covivio Hotels - Informations relatives au nombre total de droits de vote et d’actions composant le capital social
Published on 02/02/2026 at 18:00, 8 hours 27 minutes ago

Covivio - Informations relatives au nombre total de droits de vote et d’actions composant le capital social

View all LES ECHOS COMFI WIRE